The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
Open accessAbstract
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy. Methods In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR -mutated (exon 19 deletion or L858R mutation) advanced non–small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed. Research Summary Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC Results A total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib–chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib–chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib–chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy — a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents. Conclusions First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR -mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486 .)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationOverall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Self-citationCross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798
Self-citationHendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Self-citationReungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Self-citationOverall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W.-C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304594 · Cited by 672
Self-citationPaz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9363 · Cited by 517
Self-citationHosomi, Y., Morita, S., Sugawara, S., Kato, T., Fukuhara, T., Gemma, A., Takahashi, K., Fujita, Y., Harada, T., Minato, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01488 · Cited by 481
Self-citationGefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Noronha, V., Patil, V. M., Joshi, A., Menon, N., Chougule, A., Mahajan, A., Janu, A., Purandare, N., Kumar, R., More, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01154 · Cited by 418
Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03570 · Cited by 300
Peters, S., Bexelius, C., Munk, V., & Leighl, N. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.009 · Cited by 295
Lee, C. K., Davies, L., Wu, Y.-L., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw279 · Cited by 252
Self-citationHan, B., Jin, B., Chu, T., Niu, Y., Dong, Y., Xu, J., Gu, A., Zhong, H., Wang, H., Zhang, X., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30806 · Cited by 141
Cho, B. C., Han, J., Kim, S., Lee, K. H., Cho, E. K., Lee, Y., Kim, D., Kim, J.-H., Lee, G., Lee, J.-S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.025 · Cited by 104
Self-citationMiyauchi, E., Morita, S., Nakamura, A., Hosomi, Y., Watanabe, K., Ikeda, S., Seike, M., Fujita, Y., Minato, K., Ko, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02911 · Cited by 104
Self-citationPlanchard, D., Feng, P., Karaseva, N. A., Kim, S.-W., Kim, T. M., Lee, C. K., Poltoratskiy, A., Yanagitani, N., Marshall, R., Huang, X., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100271 · Cited by 77
Self-citationBhatt, V. R., Dsouza, S., Smith, L. M., Cushman‐Vokoun, A. M., Noronha, V., Verma, V., Joshi, A., Chougule, A., Jambhekar, N. A., Kessinger, A., et al. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2016.003392 · Cited by 52
Saito, R., Sugawara, S., Ko, R., Azuma, K., Morita, R., Maemondo, M., Oizumi, S., Takahashi, K., Kagamu, H., Tsubata, Y., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.023 · Cited by 33
Self-citationCosta, P. A., Saul, E. E., Paul, Y., Iyer, S. G., da Silva, L. L., Tamariz, L. J., & Junior, G. L. L. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00961 · Cited by 29
Cortellini, A., Gambale, E., Cannita, K., Brocco, D., Parisi, A., Napoleoni, L., Masedu, F., Irtelli, L., Tursi, M. D., Natoli, C., et al. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12570 · Cited by 8
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
New promises and challenges in the treatment of advanced non-small-cell lung cancer
Meyer, M.-L., Fitzgerald, B. G., Paz-Ares, L., Cappuzzo, F., Jänne, P. A., Peters, S., & Hirsch, F. R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01029-8 · Cited by 453
Self-citationLung cancer in patients who have never smoked — an emerging disease
LoPiccolo, J., Gusev, A., Christiani, D. C., & Jänne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 286
Self-citation
Metadata
- Authors
- Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C.-H., Yanagitani, N., Kim, S.-W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., Laktionov, K., Lee, C. K., Valdiviezo, N., Ahmed, S., Maurel, J.-M., Andrasina, I., Goldman, J., Ghiorghiu, D., Rukazenkov, Y., Todd, A., & Kobayashi, K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-11-23
- Volume
- 389
- Issue
- 21
- Pages
- 1935-1948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388484248
- Cited by
- 740
- References
- 23
- FWCI
- 117.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.